Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Abstract
A study that assessed the risk of diabetic ketoacidosis after the initiation of SGLT2 inhibitor therapy showed nearly twice the risk as with a DPP4 inhibitor.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SGLT inhibitors have shown significant reductions in HbA1c of 0.4-0.5%, insulin dose, and bodyweight, without increasing hypoglycaemia risk, although they raise the risk of diabetic ketoacidosis.
“SGLT inhibitors have shown significant reductions in HbA₁ c of 0•4-0•5%, insulin dose, and bodyweight, without increasing hypoglycaemia risk, although they raise the risk of diabetic ketoacidosis.5”
From The future of type 1 diabetes therapy (2025) · cites this paper as [5]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 4 · Cited by 334
- Authors
- Fralick, M., Schneeweiss, S., & Patorno, E.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-06-08
- Volume
- 376
- Issue
- 23
- Pages
- 2300-2302
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2624032915
- Cited by
- 334
- References
- 4
- Citations by year
- 2026: 14 · 2025: 31 · 2024: 31 · 2023: 31 · 2022: 24 · 2021: 49 · 2020: 47 · 2019: 47 · 2018: 39 · 2017: 21
- FWCI
- 33.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- diabetic ketoacidosis, SGLT2 inhibitors, DPP-4 inhibitors, drug safety, type 2 diabetes, adverse drug reactions, risk comparison
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Adult, Diabetes Mellitus, Humans, Hypoglycemic Agents, Middle Aged, Risk, Diabetic Ketoacidosis, Dipeptidyl-Peptidase IV Inhibitors, Propensity Score
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
